Key Highlights

• The purchase agreement covered an aggregate of 1,470,588 securities, including ADSs or prefunded warrants, each tied to 80,000 ordinary shares.

• The June 26, 2026, closing delivered the remaining 980,395 securities to investors.

• Additional warrants will be issued only after shareholder approval at the upcoming annual meeting.

Akari Therapeutics Plc (NASDAQ: AKTX) announced the completion of the final phase of its private placement under a securities purchase agreement. The transaction, initially outlined in a regulatory filing, involved the issuance of securities to a select group of investors.

Initial Closing Details

The first portion of the agreement was finalized on May 27, 2026, marking the initial delivery of securities to investors. This step set the foundation for subsequent closings, which were originally planned for later in June and July.

Amendment and Consolidation

On June 23, 2026, Akari and the investors agreed to modify the timeline by combining the remaining two closings into a single event. The amendment preserved all other terms of the original agreement.

Combined Closing Execution

The final closing took place on June 26, 2026, at which point Akari issued the remaining 980,395 securities to investors. This action fulfilled the company’s total commitment under the purchase agreement.

Structure of the Offering

The agreement permits the issuance of an aggregate of 1,470,588 securities, which may include prefunded warrants. Each prefunded warrant allows the holder to purchase an ADS representing 80,000 ordinary shares. The offering also includes additional warrants that, if approved, would provide further rights to acquire securities.

Contingent Warrants and Shareholder Vote

The issuance of the remaining warrants is dependent on approval at Akari’s annual general meeting, scheduled for June 30, 2026. The outcome of this vote will determine whether these warrants become exercisable.

Regulatory Compliance Note

Akari submitted the necessary documentation under the Securities Exchange Act of 1934, ensuring compliance with all relevant regulatory requirements.

Outlook for Investors

With the private placement now fully executed, Akari has secured the proceeds intended for its operational and strategic priorities. Investors will closely watch the June 30 shareholder vote, as its results will influence the final terms of the warrant package and the company’s capital structure moving forward. The biopharmaceutical sector often sees such placements as a means to strengthen financial flexibility while advancing clinical and commercial objectives.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.